Synergia crafts precise, comprehensive models of clients' organizations. Based on these they develop, deploy, and validate supportive interventions and computational tools that enable their clients to more effectively pursue their missions. The financing will enable Synergia to initiate the clinical development of novel therapeutics for the treatment of migraine and other neurologic disorders. Synergia will focus on sympathetic nervous system dysfunction. The sympathetic nervous system is responsible for the ability of the body to respond to stress, both physiological and psychological. A number of common medical disorders, such as migraine, are often characterized by dysfunction of the sympathetic nervous system
